June 19, 2025 11:56 AM EDTUpdated 12:38 PM
FDA+

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Zachary Brennan

Senior Editor

The FDA’s top lead­er­ship in its cell and gene ther­a­py di­vi­sion have been let go, sources told End­points News, in the lat­est shake­up at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Grail shares jump on study re­sults for can­cer test

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times